lund cancer - OmicsDI

Show results for

Unknown (3653)
Genomics (222)
Proteomics (72)
Transcriptomics (50)
Clinical (1)
Metabolomics (1)

Organisms

Homo sapiens (78)
Allexis (71)
Arabidopsis thaliana (71)
Callinectes sapidus (71)
Drosophila (71)
Drosophila melanogaster (71)
Ensifer adhaerens (71)
Entamoeba histolytica (71)
Escherichia coli (71)
Leishmania major strain Friedlin (71)
Listeria monocytogenes (71)
Medicago truncatula (71)
Methylohalobius crimeensis 10Ki (71)
Mus musculus (71)
Mycobacterium tuberculosis (71)
Oryza sativa Indica Group (71)
Physcomitrium patens (71)
Pseudomonas fluorescens WH6 (71)
Pseudomonas putida KT2440 (71)
Rattus norvegicus (71)
Saccharomyces cerevisiae (71)
Schizosaccharomyces pombe (71)
Schizosaccharomyces pombe 972h- (71)
Shigella (71)
Shigella flexneri (71)
Sinorhizobium meliloti BL225C (71)
Solanum tuberosum (71)
Staphylococcus aureus (71)
Mus musculus (6)
Rattus norvegicus (1)

Organisms

Homo sapiens (144)
Mus musculus (19)
Gallus gallus (2)

Repository

ENA (187)
pride (71)
biostudies-arrayexpress (51)
EGA (33)
geo (2)
MassIVE (1)
MetaboLights (1)

Tissue

Cell culture (22)
Epithelial cell (21)
Lung (8)
Brain (6)
Permanent cell line cell (6)
Breast cancer cell (5)
Cell suspension culture (5)
Lymph node (4)
B cell (3)
Fibroblast (3)
Mammary gland epithelial cell (3)
Blood (2)
Breast (2)
Breast epithelial cell (2)
Breast epithelium (2)
Dendritic cell (2)
HeLa cell (2)
JURKAT cell (2)
Liver (2)
Skin (2)
Soft tissue sarcoma cell (2)
Adipocyte of breast (1)
Bile duct (1)
Bone marrow (1)
Early embryonic cell (1)
Embryonic stem cell (1)
Epithelial cell of prostate (1)
Hepatocyte (1)
Leukocyte (1)
Lymphoblast (1)

Disease

Breast cancer (24)
Brain cancer (5)
Lung cancer (3)
Glioblastoma (2)
Brain glioblastoma multiforme (2)
Lung adenocarcinoma (2)
Lung small cell carcinoma (2)
Malignant neoplasm of ovary (2)
Melanoma (2)
Prostate adenocarcinoma (2)
Bladder cancer (1)
Colonic adenocarcinoma (1)
Normal (1)
Prostatic Neoplasms (1)
Acute leukemia (1)
Burkitt lymphoma (1)
Cancer (1)
Cholangiocarcinoma (1)
Colon cancer (1)
Huntington Disease (1)
Kidney cancer (1)
Lung carcinoma (1)
Lymphoma (1)
Myelodysplastic syndrome (1)
Myeloid leukemia (1)
Neuroblastoma (1)
Non-small cell lung carcinoma (1)
Pancreatic cancer (1)
Skin melanoma (1)

Technology Type

Mass Spectrometry (71)
Shotgun proteomics (44)
Affinity purification coupled with mass spectrometry proteomics (10)
Bottom-up proteomics (9)
Data-dependent acquisition (7)
Data-independent acquisition (6)
Gel-based experiment (4)
SRM/MRM (4)
SWATH MS (4)
Illumina HiSeq 2000, Affymetrix SNP 6.0 (1)
Illumina HiSeq 2000, Affymetrics_SNP_6.0- (1)
Illumina HiSeq 2000, Affymetrics_SNP_6.0-, Illumina Genome Analyzer IIx (1)
Illumina (1)
Illumina HiSeq 2000 (1)
Mass spectrometry (1)
Immunopeptidomics (1)
Top-down proteomics (1)

Instrument Platform

Illumina NovaSeq 6000 (4)
Illumina HiSeq 2000 (1)
Q Exactive HF-X (1)
Liquid Chromatography MS - positive - reverse phase (1)

Publication Date

2022 (14)
2020 (11)
2026 (10)
2015 (9)
2010 (9)
2021 (9)
2024 (8)
2023 (7)
2025 (6)
2016 (6)
2012 (6)
2011 (6)
2013 (4)
2008 (4)
2014 (3)
2009 (3)
2007 (3)
2019 (3)
2018 (3)
2017 (2)

First Public Date

2014 (54)
2023 (19)
2024 (18)
2021 (17)
2026 (14)
2015 (12)
2025 (11)
2017 (10)
2020 (8)
2018 (7)
2022 (6)
2019 (4)
2016 (4)
2013 (3)

Study status

Active, not recruiting (1)

Study type

Transcription profiling by array (30)
Comparative genomic hybridization by array (5)
RNA-seq of coding RNA (5)
Transcription profiling by tiling array (3)
ChIP-seq (2)
Methylation profiling by array (2)
RNAi profiling by array (1)
Spatial transcriptomics by high-throughput sequencing (1)
RNA-seq of total RNA (1)
Interventional (1)

Release Date

2021 (409)
2022 (350)
2023 (347)
2025 (321)
2024 (295)
2019 (283)
2020 (282)
2018 (233)
2016 (222)
2017 (187)
2015 (178)
2014 (136)
2013 (86)
2012 (80)
2011 (75)
2010 (56)
2026 (50)
2009 (32)
2008 (32)
2007 (15)
2006 (15)
2005 (6)
2003 (5)
2000 (3)
2004 (1)
2002 (1)
2001 (1)
1999 (1)
1997 (1)

Lab affiliation

Department of Immunotechnology, Lund University (3)
Dept. of Immunology, Oslo University Hospital Rikshospitalet, Oslo, Norway (2)
Div. Clinical Protein Science and Imaging, Dept. of Clinical Sciences and Dept. of Biomedical Engineering, Lund University, Sweden (2)
Division of Surgery, Oncology, and Pathology, Department of Clinical Sciences, Lund University, Solvegatan 19, 223 62, Lund, Sweden. (2)
Division of Surgery, Oncology, and Pathology, Department of Clinical Sciences. Biomedical Center – Lund University, Solvegatan 19, 223 62, Lund, Sweden (2)
Immunotechnology dept., Lund University, Sweden (2)
Institute of Clinical Sciences, Department of Oncology, Lund University, Sweden (2)
Lund University (2)
8Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, Lund, Sweden (1)
Anders H. Lund Professor, PhD Biotech Research and Innovation Centre University of Copenhagen Ole Maaloes Vej 5 DK-2200 N Copenhagen Denmark (1)
Clinical Protein Science & Imaging, Biomedical Center, Dept. of Biomedical Engineering, Lund University, Sweden. (1)
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway Institute of Clinical Medicine, University of Oslo, Oslo, Norway (1)
Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark (1)
Department of Chemical & Systems Biology Stanford University USA (1)
Department of Chemical & Systems Biology, Stanford University, USA (1)
Department of Clinical Sciences Division of Clinical Protein Science and Imganing (1)
Department of Clinical Sciences Divition of Clinical Protein Sceince and Imgaing (1)
Department of Clinical Sciences Lund, Section of Oncology, Lund University, Lund 221 85, Sweden (1)
Department of Clinical Sciences, Division of Clinical Protein Science and Imaging, Lund University, Sweden (1)
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), PO Box 8905, N-7491, Trondheim, Norway Phone: +47 72573075, Fax: +47 72576400 (1)
Department of Immunology and Transfusion Medicine, Oslo University Hospital and Hybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo. P.O. Box 1110 Blindern 0317, Oslo, Norway. (1)
Department of Laboratory Medicine, Lund University, Sweden (1)
Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden. (1)
Department of Proteomics, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark (1)
Department of Surgery, Erasmus MC-University Medical Center, Rotterdam, The Netherlands. (1)
Department of Surgery. Clincal Sciences Lund. Lund University (1)
Department of Translational Medicine, Lund University, Sweden (1)
Div. Clinical Protein Science & Imaging, Dept. of Clinical Sciences (Lund) and Dept. of Biomedical Engineering, Lund University, Lund, Sweden (1)
Division of Clinical Protein Science & Imaging, Department of Clinical Sciences (Lund), Department of Biomedical Engineering, Lund University, Lund, Sweden (1)
Division of Molecular Hematology, Department of Laboratory Medicine, Lund Stem Cell Center, Faculty of Medicine, Lund University, Lund, Sweden (1)

Keyword

Physical exercise (1)
Randomised trial (1)

Previous page
1 / 400
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 400
Next page

Sort by:

Relevance

Page size

Immunohistochemical Assays for Bladder Cancer Molecular Subtyping: Optimizing Parsimony and Performance of Lund Taxonomy Classifiers.

Not available

S-EPMC9058369 | biostudies-literature

LUND-PROBE - LUND Prostate Radiotherapy Open Benchmarking and Evaluation dataset.

Not available

S-EPMC11992069 | biostudies-literature

Expression data from breast cancer cells overexpressing NF1-C2

NF1-C2 suppresses tumorigenesis and epithelial-to-mesenchymal transition by repressing FoxF1. We used microarray to identify direct targets for NF1-C2. The human breast tumor cell line MDA-MB-436 were stably transfected with an expression plasmid including NF1-C2. RNA from these cells and wildtype c...

ORGANISM(S): Homo sapiens

2010-03-09 | E-GEOD-17636 | biostudies-arrayexpress

DIA-MS analysis of 24 breast cancer tissues

In recent years genomic and proteomic technologies have been employed in a combined effort to extrapolate key clinical and biological information of complex diseases such as cancer. Most integrative studies employ DNA and/or RNA sequencing technologies coupled to mass spectrometry-derived informatio...

ORGANISM(S): Homo sapiens (Human)

2021-04-26 | PXD021394 | Pride